Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 153

1.

Mining healthcare data for markers of the multiple sclerosis prodrome.

Högg T, Wijnands JMA, Kingwell E, Zhu F, Lu X, Evans C, Fisk JD, Marrie RA, Zhao Y, Tremlett H.

Mult Scler Relat Disord. 2018 Aug 8;25:232-240. doi: 10.1016/j.msard.2018.08.007. [Epub ahead of print]

PMID:
30121490
2.

Factors associated with perceived need for mental health care in multiple sclerosis.

Orr J, Bernstein CN, Graff LA, Patten SB, Bolton JM, Sareen J, Marriott JJ, Fisk JD, Marrie RA; CIHR Team in Defining the Burden and Managing the Effects of Immune-mediated Inflammatory Disease.

Mult Scler Relat Disord. 2018 Jul 29;25:179-185. doi: 10.1016/j.msard.2018.07.043. [Epub ahead of print]

3.

Increased Burden of Psychiatric Disorders in Inflammatory Bowel Disease.

Bernstein CN, Hitchon CA, Walld R, Bolton JM, Sareen J, Walker JR, Graff LA, Patten SB, Singer A, Lix LM, El-Gabalawy R, Katz A, Fisk JD, Marrie RA; CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease.

Inflamm Bowel Dis. 2018 Jul 7. doi: 10.1093/ibd/izy235. [Epub ahead of print]

PMID:
29986021
4.

Five years before multiple sclerosis onset: Phenotyping the prodrome.

Wijnands JM, Zhu F, Kingwell E, Zhao Y, Ekuma O, Lu X, Evans C, Fisk JD, Marrie RA, Tremlett H.

Mult Scler. 2018 Jul 1:1352458518783662. doi: 10.1177/1352458518783662. [Epub ahead of print]

PMID:
29979093
5.

Psychiatric comorbidity increases mortality in immune-mediated inflammatory diseases.

Marrie RA, Walld R, Bolton JM, Sareen J, Patten SB, Singer A, Lix LM, Hitchon CA, El-Gabalawy R, Katz A, Fisk JD, Bernstein CN; CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease.

Gen Hosp Psychiatry. 2018 Jul - Aug;53:65-72. doi: 10.1016/j.genhosppsych.2018.06.001. Epub 2018 Jun 7.

PMID:
29929117
6.

The association of fatigue, pain, depression and anxiety with work and activity impairment in immune mediated inflammatory diseases.

Enns MW, Bernstein CN, Kroeker K, Graff L, Walker JR, Lix LM, Hitchon CA, El-Gabalawy R, Fisk JD, Marrie RA; CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease.

PLoS One. 2018 Jun 7;13(6):e0198975. doi: 10.1371/journal.pone.0198975. eCollection 2018.

7.

Comorbidities Are Associated with Altered Health Services Use in Multiple Sclerosis: A Prospective Cohort Study.

McKay KA, Marrie RA, Fisk JD, Patten SB, Tremlett H.

Neuroepidemiology. 2018;51(1-2):1-10. doi: 10.1159/000488799. Epub 2018 May 15.

PMID:
29763935
8.

Diagnoses of Depression and Anxiety Versus Current Symptoms and Quality of Life in Multiple Sclerosis.

Marrie RA, Patten SB, Berrigan LI, Tremlett H, Wolfson C, Warren S, Leung S, Fiest KM, McKay KA, Fisk JD; CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis (ECoMS).

Int J MS Care. 2018 Mar-Apr;20(2):76-84. doi: 10.7224/1537-2073.2016-110.

9.

The Validity and Reliability of Screening Measures for Depression and Anxiety Disorders in Inflammatory Bowel Disease.

Bernstein CN, Zhang L, Lix LM, Graff LA, Walker JR, Fisk JD, Patten SB, Hitchon CA, Bolton JM, Sareen J, El-Gabalawy R, Marriott J, Marrie RA; CIHR Team in Defining the Burden and Managing the Effects of Immune-mediated Inflammatory Disease.

Inflamm Bowel Dis. 2018 Apr 13. doi: 10.1093/ibd/izy068. [Epub ahead of print]

PMID:
29668911
10.

Mapping the Plasticity of the Escherichia coli Genetic Code with Orthogonal Pair-Directed Sense Codon Reassignment.

Schmitt MA, Biddle W, Fisk JD.

Biochemistry. 2018 May 15;57(19):2762-2774. doi: 10.1021/acs.biochem.8b00177. Epub 2018 Apr 27.

PMID:
29668270
11.

Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study.

Wijnands JMA, Zhu F, Kingwell E, Fisk JD, Evans C, Marrie RA, Zhao Y, Tremlett H.

J Neurol Neurosurg Psychiatry. 2018 Mar 30. pii: jnnp-2017-317493. doi: 10.1136/jnnp-2017-317493. [Epub ahead of print]

PMID:
29602795
12.

Psychiatric comorbidity is associated with disability progression in multiple sclerosis.

McKay KA, Tremlett H, Fisk JD, Zhang T, Patten SB, Kastrukoff L, Campbell T, Marrie RA; CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis.

Neurology. 2018 Apr 10;90(15):e1316-e1323. doi: 10.1212/WNL.0000000000005302. Epub 2018 Mar 9.

PMID:
29523642
13.

Validation of the PHQ-9 for Suicidal Ideation in Persons with Inflammatory Bowel Disease.

Litster B, Bernstein CN, Graff LA, Walker JR, Fisk JD, Patten SB, Bolton JM, Sareen J, El-Gabalawy R, Marrie RA.

Inflamm Bowel Dis. 2018 Jul 12;24(8):1641-1648. doi: 10.1093/ibd/izy032.

PMID:
29522100
14.

Resting State BOLD Variability in Alzheimer's Disease: A Marker of Cognitive Decline or Cerebrovascular Status?

Scarapicchia V, Mazerolle EL, Fisk JD, Ritchie LJ, Gawryluk JR.

Front Aging Neurosci. 2018 Feb 21;10:39. doi: 10.3389/fnagi.2018.00039. eCollection 2018.

15.

Increased Burden of Psychiatric Disorders in Rheumatoid Arthritis.

Marrie RA, Hitchon CA, Walld R, Patten SB, Bolton JM, Sareen J, Walker JR, Singer A, Lix LM, El-Gabalawy R, Katz A, Fisk JD, Bernstein CN; Canadian Institutes of Health Research Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease.

Arthritis Care Res (Hoboken). 2018 Jul;70(7):970-978. doi: 10.1002/acr.23539. Epub 2018 May 21.

16.

Physical comorbidities increase the risk of psychiatric comorbidity in immune-mediated inflammatory disease.

Marrie RA, Walld R, Bolton JM, Sareen J, Walker JR, Patten SB, Singer A, Lix LM, Hitchon CA, El-Gabalawy R, Katz A, Fisk JD, Bernstein CN; CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease.

Gen Hosp Psychiatry. 2018 Mar - Apr;51:71-78. doi: 10.1016/j.genhosppsych.2018.01.003. Epub 2018 Jan 11.

PMID:
29353127
17.

Effects of Psychiatric Comorbidity in Immune-Mediated Inflammatory Disease: Protocol for a Prospective Study.

Marrie RA, Graff L, Walker JR, Fisk JD, Patten SB, Hitchon CA, Lix LM, Bolton J, Sareen J, Katz A, Berrigan LI, Marriott JJ, Singer A, El-Gabalawy R, Peschken CA, Zarychanski R, Bernstein CN.

JMIR Res Protoc. 2018 Jan 17;7(1):e15. doi: 10.2196/resprot.8794.

18.

Effects of physical comorbidities on disability progression in multiple sclerosis.

Zhang T, Tremlett H, Zhu F, Kingwell E, Fisk JD, Bhan V, Campbell T, Stadnyk K, Carruthers R, Wolfson C, Warren S, Marrie RA; CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis.

Neurology. 2018 Jan 30;90(5):e419-e427. doi: 10.1212/WNL.0000000000004885. Epub 2018 Jan 3.

PMID:
29298855
19.

The validity and reliability of screening measures for depression and anxiety disorders in multiple sclerosis.

Marrie RA, Zhang L, Lix LM, Graff LA, Walker JR, Fisk JD, Patten SB, Hitchon CA, Bolton JM, Sareen J, El-Gabalawy R, Marriott JJ, Bernstein CN.

Mult Scler Relat Disord. 2018 Feb;20:9-15. doi: 10.1016/j.msard.2017.12.007. Epub 2017 Dec 16.

20.

Estimating annual prevalence of depression and anxiety disorder in multiple sclerosis using administrative data.

Marrie RA, Walld R, Bolton JM, Sareen J, Walker JR, Patten SB, Singer A, Lix LM, Hitchon CA, El-Gabalawy R, Katz A, Fisk JD, Bernstein CN; CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease.

BMC Res Notes. 2017 Nov 25;10(1):619. doi: 10.1186/s13104-017-2958-1.

21.

Comorbidity increases the risk of relapse in multiple sclerosis: A prospective study.

Kowalec K, McKay KA, Patten SB, Fisk JD, Evans C, Tremlett H, Marrie RA; CIHR Team in Epidemiology and Impact of Comorbidity on Multiple Sclerosis (ECoMS).

Neurology. 2017 Dec 12;89(24):2455-2461. doi: 10.1212/WNL.0000000000004716. Epub 2017 Nov 8.

PMID:
29117961
22.

Rising incidence of psychiatric disorders before diagnosis of immune-mediated inflammatory disease.

Marrie RA, Walld R, Bolton JM, Sareen J, Walker JR, Patten SB, Singer A, Lix LM, Hitchon CA, El-Gabalawy R, Katz A, Fisk JD, Bernstein CN; CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease.

Epidemiol Psychiatr Sci. 2017 Nov 3:1-10. doi: 10.1017/S2045796017000579. [Epub ahead of print]

PMID:
29098977
23.

Increased incidence of psychiatric disorders in immune-mediated inflammatory disease.

Marrie RA, Walld R, Bolton JM, Sareen J, Walker JR, Patten SB, Singer A, Lix LM, Hitchon CA, El-Gabalawy R, Katz A, Fisk JD, Bernstein CN; CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease.

J Psychosom Res. 2017 Oct;101:17-23. doi: 10.1016/j.jpsychores.2017.07.015. Epub 2017 Aug 1.

24.

Disease-Modifying Therapies and Adherence in Multiple Sclerosis: Comparing Patient Self-Report with Pharmacy Records.

McKay KA, Evans C, Fisk JD, Patten SB, Fiest K, Marrie RA, Tremlett H.

Neuroepidemiology. 2017;48(3-4):124-130. doi: 10.1159/000477771. Epub 2017 Jul 7.

PMID:
28683461
25.

Lateralized microstructural changes in early-stage Parkinson's disease in anterior olfactory structures, but not in substantia nigra.

Joshi N, Rolheiser TM, Fisk JD, McKelvey JR, Schoffer K, Phillips G, Armstrong M, Khan MN, Leslie RA, Rusak B, Robertson HA, Good KP.

J Neurol. 2017 Jul;264(7):1497-1505. doi: 10.1007/s00415-017-8555-3. Epub 2017 Jun 26.

PMID:
28653210
26.

Cholinesterases in normal and Alzheimer's disease primary olfactory gyrus.

Hamodat H, Cash MK, Fisk JD, Darvesh S.

Neuropathol Appl Neurobiol. 2017 Dec;43(7):571-583. doi: 10.1111/nan.12423. Epub 2017 Jul 21.

PMID:
28644906
27.

Health-care use before a first demyelinating event suggestive of a multiple sclerosis prodrome: a matched cohort study.

Wijnands JMA, Kingwell E, Zhu F, Zhao Y, Högg T, Stadnyk K, Ekuma O, Lu X, Evans C, Fisk JD, Marrie RA, Tremlett H.

Lancet Neurol. 2017 Jun;16(6):445-451. doi: 10.1016/S1474-4422(17)30076-5. Epub 2017 Apr 20.

PMID:
28434855
28.

Increased incidence and prevalence of psoriasis in multiple sclerosis.

Marrie RA, Patten SB, Tremlett H, Wolfson C, Leung S, Fisk JD.

Mult Scler Relat Disord. 2017 Apr;13:81-86. doi: 10.1016/j.msard.2017.02.012. Epub 2017 Feb 20.

29.

Infection-related health care utilization among people with and without multiple sclerosis.

Wijnands JM, Kingwell E, Zhu F, Zhao Y, Fisk JD, Evans C, Marrie RA, Tremlett H.

Mult Scler. 2017 Oct;23(11):1506-1516. doi: 10.1177/1352458516681198. Epub 2016 Dec 21.

PMID:
28273769
30.

Longitudinal changes in microstructural white matter metrics in Alzheimer's disease.

Mayo CD, Mazerolle EL, Ritchie L, Fisk JD, Gawryluk JR; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage Clin. 2016 Dec 16;13:330-338. doi: 10.1016/j.nicl.2016.12.012. eCollection 2017.

31.

Hyperthermostable binding molecules on phage: Assay components for point-of-care diagnostics for active tuberculosis infection.

Zhao N, Spencer J, Schmitt MA, Fisk JD.

Anal Biochem. 2017 Mar 15;521:59-71. doi: 10.1016/j.ab.2016.12.021. Epub 2017 Jan 3.

PMID:
28062210
32.

Screening Tools for Anxiety in People with Multiple Sclerosis: A Systematic Review.

Litster B, Fiest KM, Patten SB, Fisk JD, Walker JR, Graff LA, Bolton JM, Sareen J, Marriott JJ, Berrigan LI, Bernstein CN, Zarychanski R, Singer A, Hitchon CA, Peschken CA, Marrie RA; CIHR Team “Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease”.

Int J MS Care. 2016 Nov-Dec;18(6):273-281. doi: 10.7224/1537-2073.2016-004.

33.

Modification of orthogonal tRNAs: unexpected consequences for sense codon reassignment.

Biddle W, Schmitt MA, Fisk JD.

Nucleic Acids Res. 2016 Dec 1;44(21):10042-10050. Epub 2016 Oct 23.

34.

Physical comorbidities increase the risk of psychiatric comorbidity in multiple sclerosis.

Marrie RA, Patten SB, Greenfield J, Svenson LW, Jette N, Tremlett H, Wolfson C, Warren S, Profetto-McGrath J, Fisk JD; CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis, Blanchard J, Caetano P, Elliott L, Yu BN, Bhan V, Svenson L.

Brain Behav. 2016 Jun 29;6(9):e00493. eCollection 2016 Sep.

35.

Simulation of the M13 life cycle I: Assembly of a genetically-structured deterministic chemical kinetic simulation.

Smeal SW, Schmitt MA, Pereira RR, Prasad A, Fisk JD.

Virology. 2017 Jan;500:259-274. doi: 10.1016/j.virol.2016.08.017. Epub 2016 Sep 16.

36.

Simulation of the M13 life cycle II: Investigation of the control mechanisms of M13 infection and establishment of the carrier state.

Smeal SW, Schmitt MA, Pereira RR, Prasad A, Fisk JD.

Virology. 2017 Jan;500:275-284. doi: 10.1016/j.virol.2016.08.015. Epub 2016 Aug 25.

37.

Chronic lung disease and multiple sclerosis: Incidence, prevalence, and temporal trends.

Marrie RA, Patten S, Tremlett H, Svenson LW, Wolfson C, Yu BN, Elliott L, Profetto-McGrath J, Warren S, Leung S, Jette N, Bhan V, Fisk JD.

Mult Scler Relat Disord. 2016 Jul;8:86-92. doi: 10.1016/j.msard.2016.05.009. Epub 2016 May 11.

38.

Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study.

McKay KA, Tremlett H, Patten SB, Fisk JD, Evans C, Fiest K, Campbell T, Marrie RA; CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis (ECoMS).

Mult Scler. 2017 Apr;23(4):588-596. doi: 10.1177/1352458516657440. Epub 2016 Jul 11.

39.

Fatigue and Comorbidities in Multiple Sclerosis.

Fiest KM, Fisk JD, Patten SB, Tremlett H, Wolfson C, Warren S, McKay KA, Berrigan LI, Marrie RA; CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis (ECoMS).

Int J MS Care. 2016 Mar-Apr;18(2):96-104. doi: 10.7224/1537-2073.2015-070.

40.

Health-related quality of life in multiple sclerosis: Direct and indirect effects of comorbidity.

Berrigan LI, Fisk JD, Patten SB, Tremlett H, Wolfson C, Warren S, Fiest KM, McKay KA, Marrie RA; CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis (ECoMS).

Neurology. 2016 Mar 9. pii: 10.1212/WNL.0000000000002564. [Epub ahead of print]

41.

Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis.

Zhang T, Tremlett H, Leung S, Zhu F, Kingwell E, Fisk JD, Bhan V, Campbell TL, Stadnyk K, Yu BN, Marrie RA; CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis.

Neurology. 2016 Apr 5;86(14):1287-95. doi: 10.1212/WNL.0000000000002543. Epub 2016 Mar 4.

42.

Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis.

Fiest KM, Walker JR, Bernstein CN, Graff LA, Zarychanski R, Abou-Setta AM, Patten SB, Sareen J, Bolton JM, Marriott JJ, Fisk JD, Singer A, Marrie RA; CIHR Team Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease.

Mult Scler Relat Disord. 2016 Jan;5:12-26. doi: 10.1016/j.msard.2015.10.004. Epub 2015 Oct 19. Review.

43.

Phage display selection of tight specific binding variants from a hyperthermostable Sso7d scaffold protein library.

Zhao N, Schmitt MA, Fisk JD.

FEBS J. 2016 Apr;283(7):1351-67. doi: 10.1111/febs.13674. Epub 2016 Mar 6.

44.

Evaluating Sense Codon Reassignment with a Simple Fluorescence Screen.

Biddle W, Schmitt MA, Fisk JD.

Biochemistry. 2015 Dec 22;54(50):7355-64. doi: 10.1021/acs.biochem.5b00870. Epub 2015 Dec 5.

45.

Differences in the burden of psychiatric comorbidity in MS vs the general population.

Marrie RA, Fisk JD, Tremlett H, Wolfson C, Warren S, Tennakoon A, Leung S, Patten SB; CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis.

Neurology. 2015 Dec 1;85(22):1972-9. doi: 10.1212/WNL.0000000000002174. Epub 2015 Oct 30.

46.

Comorbidity is associated with pain-related activity limitations in multiple sclerosis.

Fiest KM, Fisk JD, Patten SB, Tremlett H, Wolfson C, Warren S, McKay KA, Berrigan L, Marrie RA; CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis (ECoMS).

Mult Scler Relat Disord. 2015 Sep;4(5):470-476. doi: 10.1016/j.msard.2015.07.014. Epub 2015 Jul 29.

47.

Adverse health behaviours are associated with depression and anxiety in multiple sclerosis: A prospective multisite study.

McKay KA, Tremlett H, Fisk JD, Patten SB, Fiest K, Berrigan L, Marrie RA; CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis (ECoMS).

Mult Scler. 2016 Apr;22(5):685-93. doi: 10.1177/1352458515599073. Epub 2015 Aug 5.

48.

High incidence and increasing prevalence of multiple sclerosis in British Columbia, Canada: findings from over two decades (1991-2010).

Kingwell E, Zhu F, Marrie RA, Fisk JD, Wolfson C, Warren S, Profetto-McGrath J, Svenson LW, Jette N, Bhan V, Yu BN, Elliott L, Tremlett H.

J Neurol. 2015 Oct;262(10):2352-63. doi: 10.1007/s00415-015-7842-0. Epub 2015 Jul 24.

49.

Predictors of chronic cerebrospinal venous insufficiency procedure use among older people with multiple sclerosis: a national case-control study.

Ploughman M, Manning OJ, Beaulieu S, Harris C, Hogan SH, Mayo N, Fisk JD, Sadovnick AD, O'Connor P, Morrow SA, Metz LM, Smyth P, Allderdice PW, Scott S, Marrie RA, Stefanelli M, Godwin M.

BMC Health Serv Res. 2015 Apr 16;15:161. doi: 10.1186/s12913-015-0835-y.

50.

The Canadian survey of health, lifestyle and ageing with multiple sclerosis: methodology and initial results.

Ploughman M, Beaulieu S, Harris C, Hogan S, Manning OJ, Alderdice PW, Fisk JD, Sadovnick AD, O'Connor P, Morrow SA, Metz LM, Smyth P, Mayo N, Marrie RA, Knox KB, Stefanelli M, Godwin M.

BMJ Open. 2014 Jul 10;4(7):e005718. doi: 10.1136/bmjopen-2014-005718. Erratum in: BMJ Open. 2015;5(3):e005718.

Supplemental Content

Support Center